Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial - Test2 - elhamkhani - TriplyDB

Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial

Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial

http://www.wikidata.org/entity/Q28362149

about

Galantamine for Alzheimer's disease and mild cognitive impairment Galantamine for Alzheimer's disease Current pharmacologic options for patients with Alzheimer's disease Systematic Review: Representativeness of Participants in RCTs of Acetylcholinesterase Inhibitors Treatment guidelines for Alzheimer's disease: redefining perceptions in primary care.The effect of galantamine on brain atrophy rate in subjects with mild cognitive impairment is modified by apolipoprotein E genotype: post-hoc analysis of data from a randomized controlled trial.Early Diagnosis and Treatment of Dementia Presenting as Transient Global Amnesia in a 76-Year-Old Man.Long-term response to galantamine in relation to short-term efficacy data: pooled analysis in patients with mild to moderate Alzheimer's disease.The Effects of an Uninterrupted Switch from Donepezil to Galantamine without Dose Titration on Behavioral and Psychological Symptoms of Dementia in Alzheimer's Disease.Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials.A searchable cross-platform gene expression database reveals connections between drug treatments and disease.Pharmacological and Nonpharmacological Treatment for Apathy in Alzheimer Disease : A systematic review across modalities Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis.Efficacy study of galantamine in possible Alzheimer's disease with or without cerebrovascular disease and vascular dementia in Thai patients: a slow-titration regimen A systematic review of assessment and treatment of moderate to severe Alzheimer's disease.Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine.Clinically tested drugs for Alzheimer's disease.Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer's disease.NMDA Neurotransmission Dysfunction in Behavioral and Psychological Symptoms of Alzheimer's Disease.Galantamine versus donepezil in Chinese patients with Alzheimer's disease: results from a randomized, double-blind study.Comparative analysis of mortality in patients with Alzheimer's disease treated with donepezil or galantamine.Current experimental therapy for Alzheimer's disease Treatment strategies for the behavioral symptoms of Alzheimer's disease: focus on early pharmacologic intervention.Economic and clinical benefits of galantamine in the treatment of mild to moderate Alzheimer's disease in a Korean population: a 52-week prospective study.Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.An update on the pharmacology of galantamine.Galantamine in Alzheimer's disease.Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer's disease: a meta-analysis.Donepezil delays progression to AD in MCI subjects with depressive symptoms.DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT Have last-observation-carried-forward analyses caused us to favour more toxic dementia therapies over less toxic alternatives? A systematic review.Effect of concomitant use of memantine on mortality and efficacy outcomes of galantamine-treated patients with Alzheimer's disease: post-hoc analysis of a randomized placebo-controlled study Are the available apathy measures reliable and valid? A review of the psychometric evidence Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer's disease.Galantamine-ER for the treatment of mild-to-moderate Alzheimer's disease.Systematic Review of Sex-Specific Reporting of Data: Cholinesterase Inhibitor Example.Combination benefit of cognitive rehabilitation plus donepezil for Alzheimer's disease patients.Clock drawing and frontal lobe behavioral effects of memantine in Alzheimer's disease: a rater-blinded study.Drug therapy for Alzheimer's disease.Effects of oral rivastigmine on cognitive domains in mild-to-moderate Alzheimer's disease.

P2860

Q24244773-024D8092-9DCA-4099-8FD6-20F67E727B46 Q24246158-8E63D8F9-2A78-4D69-8B75-1636804B30CD Q24800530-2218690E-1568-456A-84D8-52F8EE70DEA6 Q26863383-50C7B3BB-48E9-4F06-AED8-2342C41FF5A2 Q30443975-EE1C257D-585F-4D35-A6B0-61789DAD41D1 Q30874688-1F56B134-82CE-4B04-9298-B130F5E4CF70 Q33210272-4C663909-9FD3-4F37-9E6E-BC5A199A2CB4 Q33790288-F6184D0D-880C-49E2-8B4A-9699CE128D74 Q33795194-B58F878C-1448-4D04-912C-9303277FFF4A Q33912750-E33FD849-DFAF-44A3-BCEA-0AD0D2CE0CC7 Q34123013-C55FF375-64D0-4070-9006-8C4E30FD9B94 Q34552380-7014A694-8F35-4116-92C2-C8DC34498665 Q34648742-F58D124D-B6FA-4D6C-8931-5B07913C2D02 Q34655353-F3377AD8-1561-4638-A2B8-1081B53445A9 Q34977044-DD6E02D7-4976-410A-ABFA-41BF3B1FB24C Q34987695-D38A9565-A525-4EF1-B195-3F6B7403C3A5 Q35164747-AA874B37-EFE0-4F94-90DC-95F9EC734B53 Q35748293-5895738D-1976-4B88-874A-D899450B1108 Q36310524-C53C5B00-357F-4442-A610-AABAB0C9547B Q36456009-00549A64-53F6-4830-992C-8D90159187AF Q36513610-8F7B7917-61CD-4173-A447-E754B16BB8EF Q36731881-D3A19B14-DBCE-4D6B-AC59-C8303B676161 Q36742405-4F37C08F-6B96-4184-B6C2-5ED026A2501A Q36854444-10338F3E-06BA-49C1-83D8-23A4C51E879E Q36897422-FF490805-3696-4259-B448-D9D16E3557FF Q37016107-1A997B1C-A8B9-4322-8640-C2337F45260E Q37035226-FA971240-8735-45C6-9D4E-8D75E5DE416D Q37193026-1693A3B9-8868-4279-9B47-29D478D341F8 Q37231378-F9FB92D8-834A-46D9-9CE1-F6A256962107 Q37295359-CF20A12D-48EE-47CA-9314-46372A905F4B Q37396299-7D91A880-4C2D-4A68-B069-E1F45985313F Q37417244-913360F4-0643-452F-9FCB-985CF5AB23CC Q37518104-17D8D23D-DC3E-4DE7-98AC-BC9FC7A1919F Q37607844-96083ABF-BD39-4DEF-B429-A94D4D551EDF Q37695074-0ABB15BE-3211-498E-859E-4C6B39E091D6 Q38612393-1BC66CCB-6BE6-4E23-AFF9-BBAF7473AA37 Q41471873-1AC6833E-79F3-4D56-9032-91A5E811985D Q42610768-4A4E1AF8-F17F-4E3E-839A-AC6418A71ECD Q42614495-1937F843-0F16-4AFD-8F5A-2B337397F790 Q43099284-F609ACA2-7DD9-4FCF-A718-FEB60B6EC536

P2860

Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial

http://www.wikidata.org/entity/Q28362149

description

2001 nî lūn-bûn

@nan

2001 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年学术文章

@wuu

2001年学术文章

@zh-cn

2001年学术文章

@zh-hans

2001年学术文章

@zh-my

2001年学术文章

@zh-sg

2001年學術文章

@yue

name

Effects of a flexible galantam ...... a randomised, controlled trial

@ast

Effects of a flexible galantam ...... a randomised, controlled trial

@en

Effects of a flexible galantam ...... a randomised, controlled trial

@nl

type

label

Effects of a flexible galantam ...... a randomised, controlled trial

@ast

Effects of a flexible galantam ...... a randomised, controlled trial

@en

Effects of a flexible galantam ...... a randomised, controlled trial

@nl

prefLabel

Effects of a flexible galantam ...... a randomised, controlled trial

@ast

Effects of a flexible galantam ...... a randomised, controlled trial

@en

Effects of a flexible galantam ...... a randomised, controlled trial

@nl

P1433

Q28362149-FB5769C8-5682-47C0-B5B3-6CF4D5672273

P1476

Q28362149-7FFFB745-9C58-4976-8D8E-9340728AFCDA

P2093

Q28362149-15992587-EC25-4382-8EF3-A7D2714002DE

Q28362149-28138FDA-1DDA-4241-91CF-EAB341FD3C8C

Q28362149-2D3B2082-7FB3-4649-B0F8-98F4ABB8FF4C

Q28362149-87730760-98E3-47E8-9347-87C3AA48AE8F

Q28362149-B09C3B8F-14B9-4228-8335-C8333BD71333

P2860

Q28362149-01D1E277-CD78-46B9-8FDD-04DE658B037B

Q28362149-04B147CE-2CBA-454E-A16C-F0E480FB1E87

Q28362149-16505F5F-1F90-46F8-BCD4-99DF35A2AE85

Q28362149-16B0C2A5-2313-4596-BD3E-7BB84F4982C6

Q28362149-1707023B-1946-4FD7-8053-50C37D945961

Q28362149-19FB430E-3FEC-4B6C-BE50-2D171906B43C

Q28362149-206E3BED-6767-4B8B-A821-38A89AECD9F5

Q28362149-2EAB3F13-3A7D-423A-B188-18A9C5AA00C7

Q28362149-2F0B31FC-363C-4D20-A006-180E9D8923C6

Q28362149-3E22BD38-60B8-4153-8AEE-FFE0EB0E3FFD

P304

Q28362149-5D6DA6EA-9A49-4AA4-AA7C-B6DB7AA6C9B5

P31

Q28362149-A8A34FD1-6556-465C-944E-619AD900C1BC

P3181

Q28362149-A3F4156B-446D-414D-BD52-080DC5B73C1B

P356

Q28362149-D781EE33-26EB-4DDF-8A52-0A718CF0A096

P407

Q28362149-A2F72404-A51E-4674-8993-D12E488F80AB

P433

Q28362149-F25AC80F-D2E7-4A33-9B2E-D9A719AA446C

P478

Q28362149-EB232BBA-2012-44D5-8A6E-4FF374682B0F

P577

Q28362149-3DAB4E41-08FF-4F50-B383-3B3E96528808

P5875

Q28362149-88109D29-2633-452A-9E08-FCABCC312A30

P698

Q28362149-6234EF82-1923-46F7-8566-509273244994

P921

Q28362149-8BE5EB89-21F5-4FB6-B2C8-A28266095BAF

P932

Q28362149-F162DC31-0CEB-4234-85D1-7B4C9E0C1AD5

P3181

P356

P1433

Journal of Neurology, Neurosurgery and Psychiatry

P1476

Effects of a flexible galantam ...... a randomised, controlled trial

@en

P2093

D Wilkinson

http://www.w3.org/2001/XMLSchema#string

J Mintzer

http://www.w3.org/2001/XMLSchema#string

K Rockwood

http://www.w3.org/2001/XMLSchema#string

L Truyen

http://www.w3.org/2001/XMLSchema#string

T Wessel

http://www.w3.org/2001/XMLSchema#string

P2860

The cholinergic hypothesis of Alzheimer's disease: a review of progress

“Mini-mental state”

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

The cholinergic hypothesis of geriatric memory dysfunction

Nicotinic acetylcholine involvement in cognitive function in animals

Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial

The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research

Improving the quality of reporting of randomized controlled trials. The CONSORT statement

Do we have drugs for dementia? No.

Effectiveness of rivastigmine in Alzheimer's disease. Improvements in functional ability remain unestablished.

P304

589-95

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2562397

http://www.w3.org/2001/XMLSchema#string

P356

10.1136/JNNP.71.5.589

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

71

http://www.w3.org/2001/XMLSchema#string

P577

2001-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11743274

http://www.w3.org/2001/XMLSchema#string

P698

11606667

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

1737604

http://www.w3.org/2001/XMLSchema#string